Novo Nordisk A/S shares soared as disappointing data from rival Eli Lilly & Co.’s closely watched obesity pill bolstered investor hopes about the Danish drugmaker’s ability to compete in the burgeoning market.
www.bloomberg.com
#Novo #Soars #Lillys #Obesity #Pill #Disappointment #Offers #Relief
Novo Soars as Lilly’s Obesity Pill Disappointment Offers Relief
